Protecting infants through covid-19 vaccination during pregnancy - ISS-G20 Laboratorium Repository

By 23 January 2023, the global covid-19 pandemic had resulted in 664 873 023 confirmed cases, and 6 724 248 deaths according to the World Health Organization.1 The initial burden of disease, in addition to marked social and economic effects, fuelled the rapid development of effective vaccines, with more than 13 billion doses administered worldwide to date. In July 2022, the US Food and Drug Administration amended its emergency use authorisation of mRNA covid-19 vaccines to include children as young as six months of age, followed by authorisation of newer bivalent mRNA vaccines for the same age group in December 2022. Although this policy greatly expands possible vaccine coverage, infants six months or younger are still left unprotected. In a linked article, Jorgensen and colleagues address this gap by evaluating the effectiveness of maternal vaccination by use of mRNA covid-19 vaccines in preventing SARS-CoV-2 infections and admission to hospital in young infants.

Entire content available on: https://www.bmj.com/content/380/bmj.p241